Updates are available Correction dated 2025-05-05

Article History

Accepted: 10 September 2024

First Online: 22 October 2024

Change Date: 13 April 2025

Change Type: Update

Change Details: The original online version of this article was revised to correct text in table 1.

Change Date: 5 May 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40272-025-00696-4

Declarations

:

: Anne Kamphuis received funding from the UNIVERSAL project, which is part of the EDCTP2 Programme supported by the European Union (grant number RIA2019PD-2882-UNIVERSAL). Anna Turkova receives core funding from the UK Medical Research Council (grants MC_UU_00004/03). No other funding was received for the preparation of this article, the open access fee was paid by Radboudumc.

: Alasdair Bamford is chair of the Penta/EACS Paediatric HIV Treatment Guidelines Working Group and has received fixed-term consultancy fees from the WHO-hosted Global Accelerator for Paediatric Formulations (GAP-f). Adrie Bekker is part of the WHO-led Paediatric Antiretroviral Working Group. Adrie Bekker is co-chief investigator of the PETITE studies, funded by UNITAID, and has received advisory board funding from ViiV Healthcare. Angela Colbers received research grants from ViiV Healthcare, Gilead, Merck and PENTA foundation, all paid to the institution. Alexandra Compagnucci is chief investigator of the SMILE trial, funded by Fondazione Penta Onlus, Gilead, Janssen, INSERM/ANRS and UK MRC. Alfredo Tagarro is researcher of the EPIICAL study funded by ViiV and a COVID-19 research grant from Pfizer, both paid to his institution, and received honoraria for webinars from Gilead and Biomerieux. Anna Turkova is co-chair of the WHO-led Paediatric Antiretroviral Working Group. Anna Turkova is chief investigator for the D3 trial (ISRCTN17157458) funded by ViiV Healthcare. Francis Ateba Ndongo is a civil servant for Cameroon, principal investigator for the UNIVERSAL-2 study, without any other funding received for the preparation of this article or any conflict of interest directly related to the content of this article. Pauline Amuge is a member of the WHO-led Paediatric Antiretroviral Working Group, and an independent TSC member for the SHIELD trial. Pauline Amuge has no financial conflict of interest. Tim R. Cressey is co-lead of the WHO-GAP-f Clinical Research Working Group and has received fixed-term consultancy fees from the Penta-ID. Tim R. Cressey is co-chief investigator of the SHIELD Study, funded by ViiV Healthcare, and co-chief investigator of the PETITE studies, funded by UNITAID. Anna Turkova, Alfredo Tagarro, Tim R. Cressey, Alasdair Bamford and Angela Colbers are members of the Penta-ID Scientific Steering Committee. Aminata Diack, Hilda Mujuru and Marc Lallemant have no conflicts of interest that are directly relevant to the content of this article.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: ACol, AK and ATu were responsible for the concept and outline of the paper. AK led the first draft of the manuscript, with input from Aba, ACol, AK, Ata and ATu. All other co-authors critically reviewed the manuscript.